EUCTR2010-024649-61-NL进行中（未招募）1 期
Pilot study: performance of the Progensa PCA3 test in post-oxytocin urine specimens - Pilot: Progensa PCA3 test in post-oxytocin urine
Radboud University Nijmegen Medical Centre0 个研究点目标入组 10 人开始时间: 2011年1月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •healthy male adult volunteers, <45 yrs old.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(prostate) cancer, family history of prostate cancer, known PSA >3.0, medication that influence PSA level (eg finasteride, dutasteride), symptoms of urinary tract infection.
研究者
相似试验
已完成
4 期
Pilot study: performance of the Progensa PCA3 test in post-oxytocin urine specimensprostate carcinoma10036958prostate cancerNL-OMON36233niversitair Medisch Centrum Sint Radboud10
进行中（未招募）
1 期
Diagnostic performance of [18F]CTT1057 PET in BCRProstate cancer with rising PSA levels [biochemical recurrence (BCR)]MedDRA version: 21.0Level: PTClassification code 10036911Term: Prostate cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003959-16-ESovartis Farmacéutica S.A.190
进行中（未招募）
1 期
Diagnostic performance of [18F]CTT1057 PET in BCRProstate cancer with rising PSA levels [biochemical recurrence (BCR)]MedDRA version: 21.0Level: PTClassification code 10036911Term: Prostate cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003959-16-FRovartis Pharma AG190
已完成
不适用
euprolide acetate 3 month depot medicine use in advance prostate cancerCTRI/2021/07/034710Bharat Serums and Vaccines ltd8
进行中（未招募）
1 期
First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole.Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis.MedDRA version: 14.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-005409-38-ESFundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)56